Efficacy of Nanofiber Sheets Incorporating Lenvatinib in a Hepatocellular Carcinoma Xenograft Model

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K08762
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 55020:Digestive surgery-related
• Research Institution: Kansai Medical University
• Principal Investigator: Matsui Kosuke 関西医科大学, 医学部, 准教授 (40460828)
• Co-Investigator(Kenkyū-buntansha): 小坂 久 関西医科大学, 医学部, 講師 (00532251) ; 海堀 昌樹 関西医科大学, 医学部, 教授 (30333199)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: レンバチニブ内包シート / 肝細胞癌

Outline of Final Research Achievements

Lenvatinib has a high response rate in unresectable advanced hepatocellular carcinoma(HCC). In this study, we investigated whether lenvatinib-incorporating poly("-caprolactone) sheets (lenvatinib sheets) as a drug delivery system (DDS) exerted antitumor effects in a murine HCC model. Tumor growth
was significantly inhibited in the lenvatinib sheet group compared with that in the no treatment and oral groups. The antitumor effect was significantly higher in the lenvatinib sheet group. Regardless of the insertion site, the serum lenvatinib levels were maintained and showed similar antitumor effects. The mitotic index was significantly inhibited in the lenvatinib sheet group compared with that in the control group. Furthermore, lenvatinib sheets improved the 30-day survival. Lenvatinib sheets showed sufficient antitumor effects.

Free Research Field

肝臓外科

Academic Significance and Societal Importance of the Research Achievements

本研究では、レンバチニブ内包PCLシート(レンバチニブシート)が、Drug Delivery System (DDS)としてマウスHCCモデルにおいて抗腫瘍効果を発揮するかを検討した。 PCLと分子標的薬のレンバチニブは組み合わせが可能であり、有効なDDSとなることが示唆された。抗癌剤は全身投与が一般的で、癌局所のみならず正常組織にも作用し副作用として現れる為、Lenvatinibのように高い抗腫瘍効果を認めるにもかかわらず、副作用のために化学療法を中止せざるを得ない場合も多い為、抗腫瘍効果を維持しつつ、副作用を軽減し得るDDSの開発応用が可能であることを示すことができた。